LitCovid-sample-Enju  

PMC:7205724 / 2420-2958 JSONTXT 16 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function

Id Subject Object Predicate Lexical cue
T377 0-8 RB denotes Moreover
T378 8-9 -COMMA- denotes ,
T379 10-14 JJS denotes most
T380 15-17 IN denotes of
T381 18-21 DT denotes the
T382 22-26 JJS denotes best
T383 27-36 JJ denotes available
T384 37-47 JJ denotes anti-viral
T385 48-54 NNS denotes agents
T386 55-58 VBP denotes are
T387 59-62 RB denotes not
T388 63-70 JJ denotes helpful
T389 71-73 IN denotes in
T390 74-77 DT denotes the
T391 78-87 NN denotes treatment
T392 88-90 IN denotes of
T393 91-99 NN denotes COVID-19
T394 101-102 DT denotes A
T395 103-113 VBN denotes randomized
T396 114-124 VBN denotes controlled
T397 125-130 NN denotes trial
T398 131-133 IN denotes of
T399 134-137 CD denotes 199
T400 138-150 VBN denotes hospitalized
T401 151-157 NNS denotes adults
T402 158-162 IN denotes with
T403 163-172 VBN denotes confirmed
T404 173-181 NN denotes COVID-19
T405 182-194 VBD denotes demonstrated
T406 195-197 DT denotes no
T407 198-204 JJ denotes actual
T408 205-215 NN denotes difference
T409 216-223 IN denotes between
T410 224-232 NNS denotes patients
T411 233-236 WP denotes who
T412 237-245 VBD denotes received
T413 246-265 NN denotes lopinavir-ritonavir
T414 266-269 CC denotes and
T415 270-278 NNS denotes patients
T416 279-282 WP denotes who
T417 283-291 VBD denotes received
T418 292-300 JJ denotes standard
T419 301-305 NN denotes care
T420 306-311 RB denotes alone
T421 312-314 IN denotes in
T422 315-323 JJ denotes clinical
T423 324-335 NN denotes improvement
T424 335-336 -COMMA- denotes ,
T425 337-342 NN denotes death
T426 343-347 NN denotes rate
T427 347-348 -COMMA- denotes ,
T428 349-352 CC denotes and
T429 353-361 JJ denotes positive
T430 362-367 NN denotes virus
T431 368-372 NN denotes test
T432 373-377 NN denotes rate
T433 378-380 IN denotes at
T434 381-384 NN denotes day
T435 385-387 CD denotes 28
T436 388-389 -LRB- denotes [
T437 389-390 CD denotes 1
T438 390-391 -RRB- denotes ]
T439 393-397 RB denotes Here
T440 398-400 PRP denotes we
T441 401-407 VBP denotes review
T442 408-420 JJ denotes intermediate
T443 421-431 NNS denotes indicators
T444 432-434 IN denotes of
T445 435-438 DT denotes the
T446 439-451 NN denotes pathogenesis
T447 452-454 IN denotes of
T448 455-463 NN denotes COVID-19
T449 464-468 WDT denotes that
T450 469-473 VBP denotes have
T451 474-477 DT denotes the
T452 478-487 NN denotes potential
T453 488-490 IN denotes of
T454 491-496 VBG denotes being
T455 497-507 VBN denotes considered
T456 508-511 IN denotes for
T457 512-515 DT denotes the
T458 516-525 NN denotes treatment
T459 526-528 IN denotes of
T460 529-537 NN denotes COVID-19
R376 T386 T377 arg1Of are,Moreover
R377 T386 T378 arg1Of are,","
R378 T379 T380 arg1Of most,of
R379 T385 T380 arg2Of agents,of
R380 T385 T381 arg1Of agents,the
R381 T383 T382 arg1Of available,best
R382 T385 T383 arg1Of agents,available
R383 T385 T384 arg1Of agents,anti-viral
R384 T379 T386 arg1Of most,are
R385 T388 T386 arg2Of helpful,are
R386 T386 T387 arg1Of are,not
R387 T379 T388 arg1Of most,helpful
R388 T386 T389 arg1Of are,in
R389 T391 T389 arg2Of treatment,in
R390 T391 T390 arg1Of treatment,the
R391 T391 T392 arg1Of treatment,of
R392 T393 T392 arg2Of COVID-19,of
R393 T397 T394 arg1Of trial,A
R394 T397 T395 arg2Of trial,randomized
R395 T397 T396 arg2Of trial,controlled
R396 T397 T398 arg1Of trial,of
R397 T401 T398 arg2Of adults,of
R398 T401 T399 arg1Of adults,199
R399 T401 T400 arg2Of adults,hospitalized
R400 T401 T402 arg1Of adults,with
R401 T404 T402 arg2Of COVID-19,with
R402 T404 T403 arg2Of COVID-19,confirmed
R403 T397 T405 arg1Of trial,demonstrated
R404 T408 T405 arg2Of difference,demonstrated
R405 T408 T406 arg1Of difference,no
R406 T408 T407 arg1Of difference,actual
R407 T408 T409 arg1Of difference,between
R408 T410 T409 arg2Of patients,between
R409 T410 T411 arg1Of patients,who
R410 T410 T412 arg1Of patients,received
R411 T414 T412 arg2Of and,received
R412 T413 T414 arg1Of lopinavir-ritonavir,and
R413 T415 T414 arg2Of patients,and
R414 T410 T416 arg1Of patients,who
R415 T410 T417 arg1Of patients,received
R416 T419 T417 arg2Of care,received
R417 T419 T418 arg1Of care,standard
R418 T419 T420 arg1Of care,alone
R419 T417 T421 arg1Of received,in
R420 T428 T421 arg2Of and,in
R421 T423 T422 arg1Of improvement,clinical
R422 T423 T424 arg1Of improvement,","
R423 T426 T424 arg2Of rate,","
R424 T426 T425 arg1Of rate,death
R425 T428 T427 arg1Of and,","
R426 T424 T428 arg1Of ",",and
R427 T432 T428 arg2Of rate,and
R428 T432 T429 arg1Of rate,positive
R429 T432 T430 arg1Of rate,virus
R430 T432 T431 arg1Of rate,test
R431 T432 T433 arg1Of rate,at
R432 T434 T433 arg2Of day,at
R433 T434 T435 arg1Of day,28
R434 T417 T436 arg1Of received,[
R435 T437 T436 arg2Of 1,[
R436 T438 T436 arg3Of ],[
R437 T441 T439 arg1Of review,Here
R438 T440 T441 arg1Of we,review
R439 T443 T441 arg2Of indicators,review
R440 T443 T442 arg1Of indicators,intermediate
R441 T443 T444 arg1Of indicators,of
R442 T446 T444 arg2Of pathogenesis,of
R443 T446 T445 arg1Of pathogenesis,the
R444 T446 T447 arg1Of pathogenesis,of
R445 T448 T447 arg2Of COVID-19,of
R446 T443 T449 arg1Of indicators,that
R447 T443 T450 arg1Of indicators,have
R448 T452 T450 arg2Of potential,have
R449 T452 T451 arg1Of potential,the
R450 T452 T453 arg1Of potential,of
R451 T455 T453 arg2Of considered,of
R452 T455 T454 arg2Of considered,being
R453 T455 T456 arg1Of considered,for
R454 T458 T456 arg2Of treatment,for
R455 T458 T457 arg1Of treatment,the
R456 T458 T459 arg1Of treatment,of
R457 T460 T459 arg2Of COVID-19,of